Sign In
Buy RLAY
$15.30
-0.400 (-2.55%)
At Close: Jun 03, 2026
Relay Therapeutics: A Precision Oncology Play Worth The Risk
02:17am, Friday, 14'th Feb 2025
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 07'th Jan 2025
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Friday, 20'th Dec 2024
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
Company to host conference call on Wednesday, December 11, 2024 at 7am ET Company to host conference call on Wednesday, December 11, 2024 at 7am ET
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)
10:35am, Friday, 06'th Dec 2024
Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
10:35am, Wednesday, 20'th Nov 2024
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
10:35am, Tuesday, 19'th Nov 2024
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
04:05pm, Wednesday, 06'th Nov 2024
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
04:05pm, Wednesday, 30'th Oct 2024
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?
09:26am, Tuesday, 17'th Sep 2024
Relay Therapeutics (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price inc
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
04:57pm, Monday, 16'th Sep 2024
Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast c
Why Relay Therapeutics Plummeted by Nearly 14% Today
06:46pm, Wednesday, 11'th Sep 2024
The biotech firmed up the details of its upcoming secondary share issue. However, the flotation will be dilutive to existing shareholders.
